SCI Foundation is now Unlimit Health. Learn more about what the change means for our ongoing efforts to eliminate neglected tropical diseases
We were founded in 2002 with a £20m grant from the Bill & Melinda Gates Foundation, and started life as a research group, the Schistosomiasis Control Initiative, within Imperial College London. So far, we have worked in close partnership with ministries of health to deliver over 1 billion treatments against parasitic infections.
We celebrated our 20th birthday
We delivered 61.5 million treatments in 13 countries in sub-Saharan Africa and have been recommended as a top charity by GiveWell for the 10th consecutive year.
SCI becomes an independent organisation – SCI Foundation
By December 2018, the SCI had facilitated the delivery of its 200 millionth treatment against parasitic worm infections.
The SCI reached an annual delivery of over 50 million treatments against parasitic worm infections.
The SCI expanded its reach after the award of the management of ICOSA (Integrated Control of Schistosomiasis and Intestinal Helminths in sub-Saharan Africa) – a programme funded by the UK Government’s Department for International Development (DFID).
By 2007, the SCI had facilitated the delivery of approximately 40 million treatments of praziquantel against schistosomiasis, and many more deworming doses of albendazole.
The SCI became a founding partner of the Global Network for Neglected Tropical Diseases which promoted the integration of control or elimination programmes against seven NTDs.
The Bill and Melinda Gates Foundation’s Global Health Programme granted a £20 million award to establish the Schistosomiasis Control Initiative (SCI) at Imperial College London, under the leadership of Professor Alan Fenwick. The grant allowed the SCI to provide a proof-of-concept for national-scale schistosomiasis programmes. It assisted the Ministries of Health and Education to deliver treatment for schistosomiasis and soil-transmitted helminthiasis in 6 countries, targeting school-age children and adults at high risk of infection.